Jeffrey Eisele Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

Jeffrey Eisele is Chief Development Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 57,208 shares of APLS, which is worth approximately $1.87 Million. The most recent transaction as insider was on Jan 30, 2024, when has been sold 971 shares (Common Stock) at a price of $65.53 per share, resulting in proceeds of $63,629. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 57.2K

0% 3M change

6.17% 12M change

Total Value Held $1.87 Million

Jeffrey Eisele Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 30 2024	SELL Open market or private sale	$63,629 $65.53 p/Share	971 Reduced 1.67%	57,208 Common Stock
Jan 29 2024	SELL Open market or private sale	$17,895 $64.14 p/Share	279 Reduced 0.48%	58,179 Common Stock
Jan 23 2024	SELL Open market or private sale	$469,904 $63.69 p/Share	7,378 Reduced 11.21%	58,458 Common Stock
Jan 22 2024	SELL Open market or private sale	$104,455 $65.0 p/Share	1,607 Reduced 2.38%	65,836 Common Stock
Jan 17 2024	SELL Open market or private sale	$341,475 $65.58 p/Share	5,207 Reduced 7.17%	67,443 Common Stock
Jan 16 2024	SELL Open market or private sale	$29,262 $66.81 p/Share	438 Reduced 0.6%	72,650 Common Stock
Jan 16 2024	BUY Grant, award, or other acquisition	-	19,508 Added 21.07%	73,088 Common Stock
Dec 27 2023	SELL Open market or private sale	$14,154 $60.23 p/Share	235 Reduced 0.44%	53,580 Common Stock
Dec 26 2023	SELL Open market or private sale	$3,934 $57.86 p/Share	68 Reduced 0.13%	53,815 Common Stock
Feb 23 2023	SELL Open market or private sale	$113,178 $68.76 p/Share	1,646 Reduced 2.96%	53,883 Common Stock
Feb 21 2023	SELL Payment of exercise price or tax liability	$48,262 $58.5 p/Share	825 Reduced 1.46%	55,529 Common Stock
Feb 21 2023	BUY Grant, award, or other acquisition	-	9,886 Added 14.92%	56,354 Common Stock
Jan 30 2023	SELL Open market or private sale	$46,587 $52.76 p/Share	883 Reduced 1.86%	46,468 Common Stock
Jan 27 2023	SELL Payment of exercise price or tax liability	$19,366 $52.77 p/Share	367 Reduced 0.77%	47,351 Common Stock
Jan 23 2023	SELL Open market or private sale	$231,026 $51.58 p/Share	4,479 Reduced 8.58%	47,718 Common Stock
Jan 20 2023	SELL Payment of exercise price or tax liability	$105,817 $52.05 p/Share	2,033 Reduced 3.75%	52,197 Common Stock
Jan 12 2023	BUY Grant, award, or other acquisition	-	22,580 Added 29.4%	54,230 Common Stock
Dec 22 2022	SELL Payment of exercise price or tax liability	$4,599 $51.68 p/Share	89 Reduced 0.28%	31,650 Common Stock
Apr 25 2022	SELL Other acquisition or disposition	-	1,250 Reduced 3.79%	31,739 Common Stock
Jan 28 2022	SELL Payment of exercise price or tax liability	$16,748 $38.59 p/Share	434 Reduced 1.3%	32,989 Common Stock
Jan 21 2022	BUY Grant, award, or other acquisition	-	26,051 Added 43.8%	33,423 Common Stock
Dec 22 2021	SELL Payment of exercise price or tax liability	$4,256 $47.82 p/Share	89 Reduced 1.19%	7,372 Common Stock
Mar 01 2021	BUY Grant, award, or other acquisition	-	1,250 Added 14.35%	7,461 Common Stock
Jan 28 2021	BUY Grant, award, or other acquisition	-	5,000 Added 44.6%	6,211 Common Stock
Dec 23 2020	BUY Grant, award, or other acquisition	-	1,211 Added 50.0%	1,211 Common Stock

Jeffrey Eisele

Chief Development Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account